Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 3/20 | 0.42 |
| ▸ | POLB | P06746 | 2/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | HKDC1 | Q2TB90 | 1/20 | 0.35 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.35 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.34 |
| ▸ | AOC3 | Q16853 | 1/20 | 0.34 |
| ▸ | NOS3 | P29474 | 1/20 | 0.34 |
| ▸ | NOS2 | P35228 | 1/20 | 0.34 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.34 |
| ▸ | TAAR1 | Q96RJ0 | 2/20 | 0.34 |
| ▸ | KLK7 | P49862 | 2/20 | 0.33 |
| ▸ | HTT | P42858 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL661362 | 0.85 | LMNA (0.41) | LMNAPOLBMEN1KMT2AHKDC1 | |
| SCHEMBL12999580 | 0.79 | LMNA (0.42) | LMNAPOLBMEN1KMT2AHKDC1 | |
| SCHEMBL9745875 | 0.77 | LMNA (0.52) | LMNAPOLBMEN1KMT2AHKDC1 | |
| SCHEMBL9716576 | 0.72 | LMNA (0.42) | LMNAPOLBMEN1KMT2AHKDC1 | |
| SCHEMBL20582787 | 0.71 | LMNA (0.35) | LMNAPOLBMEN1KMT2AHTT | |
| SCHEMBL9155644 | 0.71 | MAPT (0.43) | KMT2AHTT | |
| SCHEMBL4494436 | 0.71 | LMNA (0.45) | LMNAPOLBMEN1KMT2AHKDC1 | |
| SCHEMBL523287 | 0.71 | LMNA (0.45) | LMNAPOLBMEN1KMT2AHKDC1 | |
| SCHEMBL9716567 | 0.70 | LMNA (0.41) | LMNAPOLBMEN1KMT2AHKDC1 | |
| SCHEMBL2822248 | 0.69 | LMNA (0.43) | LMNAPOLBMEN1KMT2AHKDC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-112512497-A | Method for improving wrinkles of skin | 花王株式会社 | 2021-03-16 | — | — | CN | disclosed |
| US-20080318825-A1 | Hair Treatment Agent | THE PROCTOR & GAMBLE COMPANY (US) | 2008-12-25 | — | — | US | disclosed |
| EP-1817001-A1 | HAIR TREATMENT AGENT | Wella Aktiengesellschaft (DE) | 2007-08-15 | — | — | EP | disclosed |
| WO-2006056426-A1 | HAIR TREATMENT AGENT | WELLA AG (DE) | 2006-06-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080318825-A1 | Hair Treatment Agent | SHH, KRT18, CD44 | LMNA 2418/4885POLB 1585/4885MEN1 1319/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.